vs
Side-by-side financial comparison of Stoke Therapeutics, Inc. (STOK) and WEALTHFRONT CORP (WLTH). Click either name above to swap in a different company.
Stoke Therapeutics, Inc. is the larger business by last-quarter revenue ($158.6M vs $93.2M, roughly 1.7× WEALTHFRONT CORP). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 33.1%, a 38.0% gap on every dollar of revenue.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
Wealthfront Corporation is a financial services company based in Palo Alto, California, founded by Andy Rachleff and Dan Carroll in 2008. As of 2025, Wealthfront had $88 billion AUM across more than 1.3 million clients.
STOK vs WLTH — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $158.6M | $93.2M |
| Net Profit | $112.9M | $30.9M |
| Gross Margin | — | 89.1% |
| Operating Margin | 70.2% | 37.3% |
| Net Margin | 71.2% | 33.1% |
| Revenue YoY | 3661.1% | — |
| Net Profit YoY | 528.0% | — |
| EPS (diluted) | $1.90 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $93.2M | ||
| Q1 25 | $158.6M | — | ||
| Q4 24 | $22.6M | — | ||
| Q2 23 | $-2.5M | — |
| Q4 25 | — | $30.9M | ||
| Q1 25 | $112.9M | — | ||
| Q4 24 | $-10.5M | — | ||
| Q2 23 | $-30.7M | — |
| Q4 25 | — | 89.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 37.3% | ||
| Q1 25 | 70.2% | — | ||
| Q4 24 | -60.4% | — | ||
| Q2 23 | 1340.7% | — |
| Q4 25 | — | 33.1% | ||
| Q1 25 | 71.2% | — | ||
| Q4 24 | -46.4% | — | ||
| Q2 23 | 1235.6% | — |
| Q4 25 | — | $0.21 | ||
| Q1 25 | $1.90 | — | ||
| Q4 24 | $-0.15 | — | ||
| Q2 23 | $-0.69 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.8M | $266.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $350.1M | $125.4M |
| Total Assets | $406.9M | $810.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $266.2M | ||
| Q1 25 | $274.8M | — | ||
| Q4 24 | $128.0M | — | ||
| Q2 23 | $192.1M | — |
| Q4 25 | — | $125.4M | ||
| Q1 25 | $350.1M | — | ||
| Q4 24 | $229.0M | — | ||
| Q2 23 | $190.2M | — |
| Q4 25 | — | $810.6M | ||
| Q1 25 | $406.9M | — | ||
| Q4 24 | $271.6M | — | ||
| Q2 23 | $256.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $131.8M | — |
| Free Cash FlowOCF − Capex | $131.7M | — |
| FCF MarginFCF / Revenue | 83.0% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.17× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q1 25 | $131.8M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q2 23 | $-21.8M | — |
| Q4 25 | — | — | ||
| Q1 25 | $131.7M | — | ||
| Q4 24 | $-23.2M | — | ||
| Q2 23 | $-22.6M | — |
| Q4 25 | — | — | ||
| Q1 25 | 83.0% | — | ||
| Q4 24 | -102.7% | — | ||
| Q2 23 | 912.5% | — |
| Q4 25 | — | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.2% | — | ||
| Q2 23 | -33.8% | — |
| Q4 25 | — | — | ||
| Q1 25 | 1.17× | — | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
